Establishing a preclinical decision framework for drugs


Preclinical safety programs often follow a standard template to determine off-target effects.

However, some molecule classes and targets may raise other concerns. A well-informed, well-structured workflow needs to be thorough both in terms of information sources and methodology.

Using a theoretical drug indicated for metastatic renal cancer, in this paper, Dr. William B. Mattes examines the preclinical workflow for pharmaceutical safety analysis, including a study of:

  • The regulatory documentation for the target
  • Preclinical and clinical safety findings for approved drugs
  • Safety concerns raised in regulatory documents
  • Strategies used for similar drugs and their success


Read the case study.

To access the complimentary case study 'Establishing a preclinical decision framework for drugs', please fill in the form below.


Elsevier's R&D Solutions for Pharmacovigilance

QUOSA PV

Promote efficiency and organizational compliance by centralizing the discovery of adverse event information and automating information monitoring and triage in a scalable environment.

Learn more about QUOSA PV
Contact a QUOSA PV expert

PharmaPendium

Make more informed drug development decisions on safety and efficacy, risk assessments and mitigation, and study designs by providing researchers with searchable FDA/EMA drug approval documents and comparative drug safety data.
Learn more about PharmaPendium
Contact a PharmaPendium expert